Onset: Most users report nothing acute on first dose. Some describe a faint "alertness" or "warmth" 30–90 minutes after a 500 mg dose; this is likely the mineral + adaptogenic load rather than a sharp pharmacological hit. There is no acute psychoactive effect — shilajit is a slow-build supplement, not a same-day nootropic.

Onset of useful effect: 1–4 weeks of daily dosing before subjective changes (if any). The testosterone signal in Pandit 2016 emerged between day 30 and day 90; users who report "feel it within a week" are either responding to mineral repletion (iron, magnesium, zinc) or to expectancy.

Reported positive effects (when present):

• Sustained "background energy" or reduced afternoon fatigue
• Subjective increase in drive, motivation, or libido (often described as "T-feel" — vague but consistent)
• Better recovery between training sessions (anecdotal; consistent with the CoQ10-cycling biology)
• Improved sleep quality in a subset (counterintuitive given the adaptogenic-energy framing; possibly mineral repletion of Mg)
• "Cleaner" mental energy than caffeine in stacked reports

Reported negative effects:

• Nothing — the largest single response from non-responders
• GI upset, slight nausea on empty stomach (common, mild)
• Anxiety, restlessness, or insomnia in some users — usually at doses above 500 mg or with a high-DBP product
• "Brain fog" or fatigue — paradoxical but reported by 21 users on dopamine.club; mechanism unclear (possibly glycine-receptor agonism + susceptible individuals)
• Metallic taste (resin form), bad breath, or a faint sulfurous smell

Polarized response pattern: The most striking feature of community reports is that users split roughly 50/50 into "this is amazing" and "I felt nothing." Possible explanations: (1) product-quality variance — fake/diluted resin is widespread; (2) baseline status — men with low T or borderline iron/zinc see larger effects than men in the optimal range; (3) expectancy mediated by price and storyline (Himalayan resin carries Ayurvedic mystique; people who buy in to the story respond to the story).

For Dylan specifically: With already-normal baseline testosterone (likely 600–900 ng/dL range pre-bloodwork), well-nourished, on a comprehensive V4 stack, the expected acute subjective response is modest-to-null. The most likely felt effect, if any, is slightly better recovery between BJJ sessions over a 4-8 week trial window.

• Pharmacological tolerance: low to none. No documented receptor downregulation or efficacy decay across the 90-day trials. The mechanism (mitochondrial redox cycling + steroidogenic enzyme upregulation) doesn't predict the kind of homeostatic counter-regulation that drives tolerance in adaptogens like ashwagandha or stimulants.
• Subjective tolerance: Some users report the initial energy "novelty" fades after 2–4 weeks while a lower-grade baseline benefit persists. This is consistent with placebo-component decay rather than pharmacological tolerance.
• Recommended cycle: Continuous use is appropriate if responding. The Pandit data justifies 90-day continuous, and traditional use is year-round. Some users prefer 8-on / 2-off out of caution — no harm, no clear benefit.
• Reset protocol: Not applicable; tolerance is not the dominant pharmacology.

Synergistic with

• CoQ10 (100–200 mg/day): The natural pairing. Shilajit's fulvic acid recycles CoQ10 between ubiquinone and ubiquinol states; co-administration produces additive effects on mitochondrial output and exercise capacity (Das 2016 preclinical + small human signal). For athletes: strongest stacking case.
• Creatine monohydrate (5 g/day): Both support ATP regeneration via different pathways (creatine = phosphocreatine reserve; shilajit = oxidative phosphorylation efficiency). No interaction, additive on energy + recovery. Already in Dylan's V4 stack.
• Zinc + magnesium: Fulvic acid improves mineral absorption; pairing with Zn + Mg is sensible for athletes who tend toward deficiency. Already in V4.
• Tongkat Ali (Eurycoma longifolia): The classic "natural T booster" pair. Tongkat ali lowers SHBG (raising free T); shilajit raises total T production. Mechanistically distinct, additive on the T-axis. Caution: stack increases potential for androgenic side effects (acne, irritability) — monitor. Per dopamine.club, this is the #1 most-combined-with compound (178 reports).
• Ashwagandha: Both have testosterone-supportive signals; ashwagandha primarily via cortisol reduction, shilajit via direct steroidogenic enzyme upregulation. Plausibly additive. Watch for over-sedation if both at high doses.
• Vitamin D3 + K2: Vitamin D status is the strongest single modulator of testosterone in deficient men — fix D first, then layer shilajit. Already in V4.
• L-citrulline / arginine: Cardiovascular + erectile-function adjuncts; no interaction with shilajit, plausible additive for libido-focused stacks.

Avoid stacking with

• Levothyroxine / liothyronine (Synthroid, Cytomel): Mineral content + fulvic-acid chelation reduces thyroid hormone absorption. Separate by 4+ hours if both needed. Monitor TSH if starting or stopping shilajit on stable thyroid therapy.
• Iron supplements at high dose, especially in hemochromatosis carriers: Compounds iron-overload risk. If iron supplementation is needed, separate timing and re-check ferritin/transferrin saturation.
• Lithium: Theoretical concern via renal/electrolyte modulation; monitor lithium levels if introducing shilajit (rare relevance, but flagged in interaction reviews).
• Warfarin / anticoagulants: Theoretical CYP modulation + trace vitamin K content in unrefined product. Monitor INR if combining. DOACs (apixaban, rivaroxaban) — less concern given different metabolic pathway, but no clinical data.
• MAOIs (tranylcypromine, phenelzine): Theoretical sympathomimetic concern given uncharacterized DBP content. Low-evidence flag; if Dylan ever ends up on an MAOI, drop shilajit.
• TRT (exogenous testosterone): Redundant. Shilajit's mechanism is upregulating endogenous steroidogenesis; on TRT the HPG axis is suppressed and shilajit can't do its main job. Save the money.

Neutral / safe co-administration

• Caffeine, L-theanine, modafinil, bromantane, semax, selank — no known interactions.
• Standard V4 stack (Mg, NAC, omega-3, citicoline, vitamin D3/K2, PS, curcumin) — no interactions, plausibly complementary on antioxidant + mitochondrial axes.
• Peptides (BPC-157, TB-500, Selank, Semax, Adamax) — neutral.
• Most SSRIs, SNRIs, atypicals (escitalopram, bupropion): no documented interactions. Speculative caution flagged in some interaction databases but no clinical signal.

Shilajit's pharmacokinetic profile:

• Fulvic acid: rapidly absorbed, peak 1–3 hours, half-life ~6–8 hours, primarily renal excretion.
• DBPs: less-characterized; lipophilic, longer plasma half-life (~10 hours estimated).
• Minerals: standard absorption kinetics by element.
• Minimal CYP metabolism for the main bioactives — most clearance is renal. This is a relatively "clean" PK profile compared to most herbs.

Clinically meaningful interactions:

1. Levothyroxine / liothyronine — reduced absorption (KNOWN)

• Mineral content + fulvic-acid chelation forms insoluble complexes with thyroid hormone in the gut.
• Separate by ≥4 hours. Monitor TSH if shilajit is added or removed from a stable thyroid regimen.

2. Iron supplementation — additive absorption (KNOWN, sometimes useful, sometimes risky)

• Fulvic acid enhances Fe²⁺ uptake. Useful in deficiency; problematic in HFE-variant carriers.
• Practical implication: don't routinely combine high-dose iron with shilajit unless deficiency is documented and being treated.

3. Anticoagulants (warfarin, theoretical for DOACs) — possible INR fluctuation

• Mixed potential effects: humic-fraction CYP modulation, trace vitamin K in unrefined product. Monitor INR on warfarin if combining; DOACs likely safer but uncharacterized.

4. Lithium — theoretical renal/electrolyte interaction

• Narrow therapeutic window; monitor levels if introducing shilajit. Rare combination in practice.

5. Antihypertensives — additive BP lowering

• Shilajit has mild hypotensive effect (~3–5 mmHg). Usually not clinically meaningful; in a patient near hypotension threshold, additive caution warranted.

6. Estrogenic-active drugs (estradiol therapy, HRT)

• Theoretical: shilajit raises androgenic precursors that can aromatize. Limited clinical relevance for most users; flagged in interaction databases.

7. Finasteride / dutasteride

• Shilajit raises total T while 5α-reductase inhibitors lower DHT conversion. Theoretical antagonism of the therapeutic goal in BPH or hair-loss management. Probably modest in practice; flagged for completeness.

8. Stimulants (lisdexamfetamine, methylphenidate, modafinil)

• No known direct interaction. Speculative additive sympathomimetic effects; not clinically significant in standard doses. Many users in cognitive-enhancement stacks combine successfully.

9. SSRIs / SNRIs / MAOIs

• No documented PK interactions. Speculative serotonergic concern flagged for MAOIs based on uncharacterized DBP content; treat as low-evidence caution.

HFE (hemochromatosis gene) — most actionable PGx flag.

• rs1800562 (C282Y) and rs1799945 (H63D) are the two main HFE variants.
• C282Y homozygotes (~0.4% of Northern European descent): high penetrance hemochromatosis; shilajit + fulvic-acid-enhanced iron absorption is a real additive risk. Avoid.
• C282Y heterozygotes or H63D homozygotes: lower-penetrance iron-loading tendency; check baseline ferritin and transferrin saturation; reasonable to use with monitoring.
• For Dylan: HFE variants are reportable in 23andMe raw data via Promethease. Check this before starting shilajit. Family history of liver disease, diabetes, or unexplained fatigue in male relatives elevates concern.

MTHFR / methylation polymorphisms: No specific actionable interaction; shilajit doesn't significantly affect methylation pathways.

AR (androgen receptor) CAG repeat: Shorter CAG repeats (more sensitive AR) may amplify subjective response to small T increases. Speculative; no shilajit-specific PGx data.

CYP polymorphisms: Largely irrelevant given shilajit's predominantly non-CYP metabolism. Doesn't affect efficacy or side-effect risk in meaningful ways.

SHBG variants (rs1799941, rs6258, rs6259): Modulate free vs. total T response; shilajit's effect on total T may translate into varying free-T impact by genotype. Not actionable in clinical practice.

Practical for Dylan: Run HFE before starting (23andMe report due June 2026). Everything else is non-actionable curiosity. If HFE clean, no PGx blockers.

Vendor selection criteria (apply to anything you consider):

1. Published third-party COA (heavy metals: Pb, As, Hg, Cd, Cr; microbial: yeast, mold, E. coli, Salmonella). If you can't find a COA on the vendor's site or by emailing, walk away.
2. Standardization to fulvic acid percentage (≥50%) and ideally DBP percentage (≥10%). Brands that won't disclose are signaling that there's nothing to disclose.
3. PrimaVie® trademark or equivalent named research-grade extract for highest-evidence option.
4. Reasonable price — $0.20/dose floor for purified, certified product. Anything dramatically cheaper is suspicious.
5. No "miracle" marketing claims — vendors making 9×-energy / instant-T-boost claims are pattern-matched to the unregulated supplement segment.

For Dylan: PrimaVie 250 mg b.i.d. (Double Wood or Pure Encapsulations) is the cleanest sourcing choice. ~$0.50/day, ~$15/month for the 90-day trial dose. The COA-verified premium is real and worth paying.

What to NOT do: buy resin off Instagram from someone with "authentic Himalayan" in the bio. The price you save is a small fraction of what a heavy-metal panel costs to verify, and the worst-case outcome is years of subclinical accumulation you only catch on bloodwork.

Baseline (before starting)

• Total testosterone, free testosterone, SHBG, DHEAS — primary outcome to monitor for the T effect.
• LH, FSH — Pandit data showed both rose with shilajit; useful for confirming HPG-axis activity.
• Estradiol — aromatization concern if T rises substantially; baseline + recheck at 8 weeks.
• Ferritin + transferrin saturation — iron-loading screen. If TSAT >45% or ferritin >300 ng/mL in a male, flag for HFE check before starting.
• HFE genotype (from 23andMe raw data via Promethease, or via standalone genetic test) — C282Y, H63D status.
• Comprehensive metabolic panel — ALT, AST, BUN, creatinine, electrolytes. Baseline for any chronic supplement.
• CBC — hemoglobin, hematocrit, MCV. Iron-status complement.
• TSH, fT4 — baseline thyroid (relevant for interaction monitoring + general health).
• CoQ10 plasma level (optional) — if pairing with CoQ10 supplementation, baseline informs whether you're starting deficient.
• Heavy-metal panel (urine or hair) — overkill for the average user, sensible if there's any prior history of contaminated supplement use or environmental lead/mercury exposure. Most important: re-check at month 6 if using shilajit chronically with anything less than PrimaVie-grade product.

During use

• Subjective fatigue, recovery, libido, mood VAS daily for first 4 weeks — capture the response (or non-response) cleanly. Most useful single data point for decision to continue.
• Resting HR + BP weekly — shilajit modestly lowers BP; track if borderline normotensive.
• Sleep quality (Oura, ring-health, subjective) — flag insomnia signal early.

Repeat (8–12 weeks)

• Total + free testosterone, DHEAS, LH, FSH, estradiol — primary efficacy check.
• Ferritin + TSAT — iron-loading monitor.
• ALT/AST — any hepatic signal.
• CBC — Hb/Hct rise sometimes seen with T increase.

Long-term (every 6 months if continuous use)

• Ferritin + TSAT — flag emerging iron overload before symptoms.
• CMP + CBC — annual baseline.
• Heavy-metal panel — only if product quality is uncertain or symptoms emerge.